Bladder cancer patients who Can't take chemo may get new option

NCT ID NCT05241340

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, feasible, and can eliminate cancer in the bladder at the time of surgery. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sasanlimab (an immunotherapy drug) and stereotactic body radiation therapy (focused radiation)
What this could lead to
If successful, this combination could offer a new treatment option for bladder cancer patients who cannot receive standard chemotherapy, potentially improving outcomes before surgery.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The treatment also carries risks of side effects from both immunotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Houston Methodist Hospital

    Houston, Texas, 77006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.